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Abstract
Caspase-2 is a highly conserved cysteine protease with roles in apoptosis and tumor suppression. Our recent findings
have also demonstrated that the tumor suppression function of caspase-2 is context specific. In particular, while
caspase-2 deficiency augments lymphoma development in the EμMyc mouse model, it leads to delayed
neuroblastoma development in Th-MYCN mice. However, it is unclear how caspase-2 mediates these differential
outcomes. Here we utilized RNA sequencing to define the transcriptomic changes caused by caspase-2 (Casp2−/−)
deficiency in tumors from EμMyc and Th-MYCN mice. We describe key changes in both lymphoma and
neuroblastoma-associated genes and identified differential expression of the EGF-like domain-containing gene, Megf6,
in the two tumor types that may contribute to tumor outcome following loss of Casp2. We identified a panel of genes
with altered expression in Th-MYCN/Casp2−/− tumors that are strongly associated with neuroblastoma outcome, with
roles in melanogenesis, Wnt and Hippo pathway signaling, that also contribute to neuronal differentiation. In contrast,
we found that key changes in gene expression in the EμMyc/Casp2−/− tumors, are associated with increased immune
signaling and T-cell infiltration previously associated with more aggressive lymphoma progression. In addition,
Rap1 signaling pathway was uniquely enriched in Casp2 deficient EμMyc tumors. Our findings suggest that Casp2
deficiency augments immune signaling pathways that may be in turn, enhance lymphomagenesis. Overall, our study
has identified new genes and pathways that contribute to the caspase-2 tumor suppressor function and highlight
distinct roles for caspase-2 in different tissues.
Introduction
The role of caspases in tumor suppression has been
largely ascribed to their established function in cell death1.
Recent experimental evidence also suggests that non-
apoptotic roles for caspases, including cell proliferation,
inflammation, migration, or invasion, can contribute to
tumorigenesis2,3. These features are well-established
hallmarks of cancer, both independently and in
co-operation with cell death evasion4, and may determine
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caspase contribution to both tumor suppression and
tumor promotion in certain contexts3. While the
mechanisms that regulate caspase functions in tumor-
igenesis are still unclear, there is evidence to suggest that
caspases mediate their differential functions in a devel-
opmental and tissue-specific manner1,2.
Caspase-2 is the most evolutionarily conserved member
of the mammalian caspase family5, with roles in apoptosis6,
tumor suppression7–11, genomic stability12, DNA damage
response12,13, oxidative stress response, metabolism, and
ageing6,14–18. While mice deficient for the caspase-2 gene
(Casp2−/−) do not develop spontaneous age-related
tumors19, they show enhanced genomic instability and
increased tumorigenesis in different mouse models,
including EμMyc lymphomas7,20, Atm−/−thymomas8;
MMTV/c-neu mammary tumors11, K-Ras-induced lung
tumors10, and DEN-induced hepatocellular carcinoma
(HCC)21. Recent studies suggest that caspase-2 mediates its
tumor suppressor function by inducing senescence and/or
apoptosis of aneuploid cells22,23. As a consequence, loss of
caspase-2 leads to the survival of abnormal, multinucleated,
and aneuploid cells, which are features of mitotic cata-
strophe and susceptibility to tumorigenesis15,21,22.
Correlative evidence supports a tumor suppressor
function for caspase-2. The human CASP2 gene on
Ch7q34, is part of a region frequently deleted in hema-
tological malignancies24. In addition, reduced CASP2
expression has been reported in lymphoma and leukemia
and correlates with poor prognosis in AML and ALL25,26.
Somatic mutations in CASP2, although rare, are found in
cases of high-grade colon and gastric cancer, lung, skin,
and breast cancer19,27,28. Furthermore, in colorectal can-
cer reduced CASP2 expression is caused by loss of its
transcriptional regulator BCL9L, and is a key cause of
aneuploidy tolerance, tumor progression, and resis-
tance29. In contrast, Casp2 deficiency in mice does not
affect tumor onset or progression following 3-
methylcholanthrene (3-MC)-induced fibrosarcoma or
irradiation-driven lymphoma20. Our previous studies have
also demonstrated that Casp2 loss delays neuroblastoma
development in the Th-MYCNmouse model, and that low
CASP2 expression correlates with increased survival in
human neuroblastoma30. These findings suggest that
caspase-2 has a context/tissue-specific function in tumor
suppression and that both tissue and genomic variability
can cooperate with caspase-2 to determine tumor out-
come. To understand how caspase-2 mediates its differ-
ential functions in tumor suppression, it is important to
determine if disruption of additional genes co-operate
with caspase-2 in tissue-specific contexts.
In this study, we comparatively analyzed the tran-
scriptomes of Casp2−/− tumors from EμMyc and Th-
MYCN mice to identify changes in transcriptional tumor
networks that are influenced by caspase-2 deficiency.
While we identified several unique genes that were
aberrantly expressed in the Casp2−/− tumors, we found
that Megf6/EGFL3 was the only gene that was differen-
tially expressed in the two tumor types. Our study also
identified several enriched pathways and gene signatures
specific to EμMyc/Casp2−/− or Th-MYCN/Casp2−/−
tumors that may be associated with enhanced EμMyc-
induced lymphomas and/or delayed Th-MYCN-mediated
neuroblastoma. The cross-tumor-specific transcriptional
aberrations are highly indicative of distinct roles for
caspase-2 during neuronal and B-cell development that
perhaps influence its tumor suppressor function.
Results
RNA-seq analysis of Th-MYCN and EμMyc tumors from
Casp2−/− mice
To identify the transcriptomic differences in tumors from
Casp2−/− mice that are associated with delayed Th-MYCN
induced neuroblastoma30 and/or enhanced EμMyc lym-
phoma development7, we carried out RNA sequencing on
tumor tissue isolated from Th-MYCN and Th-MYCN/
Casp2−/− or from EμMyc and EμMyc/Casp2−/− mice
(Fig. 1a, Supplementary Tables S1a-b). Multidimensional
scaling plots showed that the EμMyc and Th-MYCN tumor
transcriptomes form distinct clusters (Supplementary Fig-
ure S1a), highlighting differences in gene expression chan-
ges between the two tumor types.
Comparisons of the differentially expressed genes (DEGs)
were performed between (i) WT and Casp2−/− tumors to
identify genes associated with tumorigenesis following
Casp2 loss and (ii) between the EμMyc/Casp2−/− and
Th-MYCN/Casp2−/− tumor samples, to narrow down
candidate genes affected by Casp2 deficiency and/or that
enhance lymphomagenesis in EμMyc/Casp2−/− mice.
These DEGs are summarized as volcano plots (Fig. 1b,
Supplementary Tables S2a-f). From the heat-maps, it is
clear that Casp2 deficiency changes the expression of
many genes, with more downregulated genes in Th-MYCN/
Casp2−/− compared to Th-MYCN tumors (Fig. 1c) and
more upregulated genes in EμMyc/Casp2−/− versus EμMyc
tumors (Fig. 1d, Supplementary Tables S3a-b).
In total, 13,714 genes were included for analysis in each
comparison group (Supplementary Tables S2a-f). Of these,
108 DEGs were identified in the Th-MYCN/Casp2−/−
versus Th-MYCN tumor comparison and 197 DEGs in the
EμMyc/Casp2−/− versus EμMyc tumors (fold change [FC]
> 2 and <−2; FDR < 0.05). As expected, there were exten-
sive differences in gene expression when comparing the two
different tumor types, including 6601 DEGs when com-
paring EμMyc to Th-MYCN tumors and 6674 DEGs in the
EμMyc/Casp2−/− versus Th-MYCN/Casp2−/− tumor
comparison. A 4-way Venn diagram identified several
exclusive and common DEGs between each comparison
group (Fig. 1e, Supplementary Table S4a). In particular, the
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Th-MYCN/Casp2−/− comparison identified four unique
downregulated genes (Ncor2, Diras2, Ednrb, Shb) and one
upregulated (Eya2) gene, with roles in transcription
(Ncor2), signal transduction (Ednrb, Shb), melanogenesis
(Ednrb), and DNA damage repair (Eya2). Two of the unique
EμMyc/Casp2−/− genes have associated roles in transcrip-
tion regulation (Six5) and calmodulin binding (Nrgn)
and have been previously associated with lung squamous
cell carcinoma, breast cancer (Six531,32), and T-cell
lymphoma (Nrgn33). Tdrd5 was excluded as it was only
increased in one out of three biological replicates. Sig-
nificant downregulation of Casp2 was also verified in the
EμMyc/Casp2−/− comparison and Casp2 gene deletion was
confirmed by genotyping and immunoblotting in all tumor
samples.
To identify common genes that are significantly altered in
the Casp2−/− samples, the DEGs were subdivided into
upregulated and downregulated lists, illustrated in a Venn
diagram (Fig. 2a). This identified 86 uniquely down-
regulated and 21 upregulated genes in Th-MYCN/Casp2−/−
versus Th-MYCN tumors and 38 downregulated and 158
upregulated genes in EμMyc/Casp2−/− versus EμMyc
tumors (Fig. 2a, Supplementary Table S4b). There was also
a single overlapping gene; Megf6 (Multiple EGF-Like
Domains 6) differentially altered in EμMyc/Casp2−/− and
Th-MYCN/Casp2−/− tumors, and this was validated by
quantitative PCR in additional tumor samples (Fig. 2b).
We used R2: Genomics Analysis and Visualization
Platform, to examine the correlation between Megf6
transcript expression and clinical outcome in various
human neuroblastoma and B-cell lymphoma publicly
available expression array data sets. Our previous data
showed that Casp2 levels correlated with clinical outcome
in a subset of MYCN non-amplified human neuro-
blastomas30. Here, we also found that higher Megf6
transcript levels are associated with poor outcome in this
neuroblastoma subset (Fig. 2c), and this is consistent with
our RNA-seq data and the delayed tumorigenesis
observed in the Th-MYCN/Casp2−/− mouse model30. We
did not find any significant association in MYCN-ampli-
fied neuroblastoma. In contrast, we found there was a
trend for lower Megf6 expression being predictive of
poorer B-cell lymphoma outcome (e.g., Xiao – 420,
fRMA-u133p2 dataset; P= 0.061) (Fig. 2d). Notably, high
Megf6 expression in B-cell lymphomas also showed a
somewhat poor survival outcome, indicating that Megf6
levels are probably not predictive of lymphoma
progression.
Functional enrichment analysis of genes in Th-MYCN/
Casp2−/− tumors
We next identified significantly altered gene ontology
processes that were enriched in Casp2−/− tumors, com-
pared to their WT counterparts. We firstly analyzed the
DEGs in the Th-MYCN/Casp2−/− versus Th-MYCN tumor
comparison. While there were no detected ontology terms
associated with the small upregulated gene list (n= 21), the
87 downregulated genes were associated with 10 categories
of ‘Biological Process’ (BP), 4 categories of ‘Molecular
Function’ (MF), and 9 categories of ‘Cellular Component’
(CC) (P < 0.05, Fisher’s exact test) (Fig. 3a, Supplementary
Table S5a). The top BP was cell differentiation
(GO:0030154) (Fig. 3a, Supplementary Table S5a), with
many of these genes also being associated with the BPs of
transcriptional regulation from RNA polymerase II pro-
moter (GO:0000122) and multicellular organismal devel-
opment (GO:0007275). This indicates that Casp2 loss can
affect neuronal differentiation and gene transcription in
neuroblastoma. Of note, response to hypoxia (GO:0001666)
and ischemia (GO:0002931), processes previously asso-
ciated with caspase-2 function34–37 were also enriched.
KEGG pathway analysis identified melanogenesis as the
only enriched pathway, associated with four down-
regulated genes (Ednrb, Mitf, Lef1, Camk2a) (Fig. 3b,
Supplementary Table S6a). Further analysis using
REACTOME and PANTHER classification systems also
identified G-alpha (q) signaling events (P= 0.03),
inflammation mediated by chemokine and cytokine sig-
naling pathway (P= 0.018) (Supplementary Table S6a).
Gene set enrichment analysis (GSEA)38, using the gene
list ranked by the FDR score, confirmed significant
enrichment of each of these pathways (Fig. 3c).
Functional enrichment analysis of genes in EμMyc/Casp2−/−
tumors
Analysis of GO terms in the EμMyc/Casp2−/− versus
EμMyc tumor comparison identified several BPs associated
the 159 upregulated genes, including immune response
(see figure on previous page)
Fig. 1 Experimental design and transcriptome profile of tumors from Th-MYCN/Casp2−/− and EµMyc/Casp2−/− mice. a Experimental design
for RNA-seq and analysis of differentially expressed genes (DEGs) from tumor tissue. b Volcano plot illustrating DEGs in a comparison of Th-MYCN/
Casp2−/− and Th-MYCN tumor samples (top) or EµMyc/Casp2−/− and EµMyc tumor samples. Colored points represent all DEGs (cut-off FDR < 0.05)
with fold change > 2, that are either overexpressed (red) or underexpressed (blue) in Casp2−/− compared with WT tumor counterparts. For a
complete list of DEGs, see Supplementary Tables S2a and S2b. c, d Heat-maps of DEGs when comparing c Th-MYCN/Casp2−/− and Th-MYCN and
d EµMyc/Casp2−/− and EµMyc tumor transcriptomes. Heat-maps display the number of increased (red) or decreased (blue) genes. For gene lists
associated with heat-maps see Supplementary Tables S3a and S3b. e Four-way Venn diagram summary of unique and overlapping DEGs in the
indicated comparison groups. The list of unique and overlapping genes in each group is provided in Supplementary Table S4a
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(GO:0002250, GO:0006955), immune system process
(GO:0002376), T-cell activation (GO:0042110), T-cell
differentiation (GO:0046632, GO:0045582, GO:0033077,
GO:0030217), and inflammatory response (GO:0006954)
(Fig. 4a, Supplementary Table S5b), indicative of a sig-
nificant immune responses in EμMyc/Casp2−/− tumors.
Increased processes commonly associated with tumorigen-
esis including signal transduction (GO:0035556,
GO:0007165, GO:0009966, GO:0007169, GO:0070373), cell
proliferation (GO:0042127, GO:0008285), and negative
regulation of cell adhesion (GO:0007162) were also enri-
ched (Fig. 4a and Supplementary Table S5b).
Consistent with the enriched BPs, KEGG pathway
analysis identified T-cell receptor signaling and primary
immunodeficiency as the most significantly altered
pathways followed by cell adhesion molecules and
Rap1 signaling (Fig. 4b, Supplementary Table S6b).
All pathways were significantly enriched when analyzed
using GSEA (Fig. 4a, c), suggesting that caspase-2 may
have a role in regulating T-cell signaling and/or
Rap1 signaling to influence lymphoma development in
EμMyc mice.
Differential expression of genes in caspase-2 deficient
tumors associated with increased survival in human
neuroblastoma
To identify genes associated with delayed neuro-
blastoma development in Th-MYCN/Casp2−/− mice, we
examined various molecular biomarkers of neuro-
blastoma development and prognosis39,40. The expression
Fig. 2 Comparison of upregulated and downregulated genes in Th-MYCN/Casp2−/−and EµMyc/Casp2−/−tumors. a Four-way Venn diagram
summary illustrating common and exclusive upregulated and downregulated genes when comparing Th-MYCN/Casp2−/− versus Th-MYCN and
EµMyc/Casp2−/− versus EµMyc tumor transcriptomes (FC > 2 and <−2; FDR < 0.05). Complete gene lists are provided in Supplementary Table S4b.
b Quantitative PCR analysis of differentially expressed Megf6 gene from the indicated tumor groups. Values represent means ± S.E.M, with P-values
indicated (n= 9/group). c, d Kaplan–Meier plots showing the association of Megf6 expression with patient survival in Neuroblastoma (c) and B-cell
lymphoma (d)
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levels of several favorable neuroblastoma genes were
found to be significantly altered in Th-MYCN/Casp2−/−
tumors, including increased expression of Slc18A1, Vip,
and reduced expression of Gata2, Gch1, Fgr, and Six6.
While the decrease in tyrosine hydroxylase (Th) expres-
sion was not significant in the biological replicates
(FDR =0.584) (Fig. 5a, Supplementary Table S7a), we did
note that several genes adjacent to Th on chromosome 7
(Ascl2, Igf2, and H19) were also somewhat decreased
(Supplementary Table S7b). This suggests this gene
region may be affected in some cells.
To determine the correlation between the expression
of these genes and neuroblastoma survival, we analyzed
data from published studies along with publicly available
expression array data sets from primary human neuro-
blastoma tumor samples (R2 database). Overall, we
found that downregulation of 7 genes (Crb1, Lrrc9,
Rcn1, Rtl1, Shisa3, Six6, St18) and upregulation of 2
genes (C1ql3, Slc18A1), are strongly predictive of
favorable neuroblastoma outcome (Fig. 5b, Supple-
mentary Table S7a), consistent with delayed tumor
development in Th-MYCN/Casp2−/− mice30.
Fig. 3 Functional category enrichment analysis of differentially expressed genes in Th-MYCN/Casp2−/−tumors. a Gene Ontology annotation
analysis summary of enriched biological processes associated with unique downregulated genes in Th-MYCN/Casp2−/− tumors (n= 87). Complete
lists are provided in Supplementary Table S5a. b Pathway enrichment analysis (KEGG and REACTOME), of the differentially expressed downregulated
genes in Th-MYCN/Casp2−/− tumors (n= 87). Complete lists are provided in Supplementary Table S6a. The number of genes associated with each
biological process and pathway is indicated. Dotted line indicates significance cut off (-log10 (P-value), Fisher's exact test). c Illustration of GSEA score
curves. Enrichment plots are shown for the identified upregulated and downregulated pathways from (b) in the Th-MYCN/Casp2−/− tumor
comparison group. Black bars represent the position of members of the category in the ranked list together with the running enrichment score
(plotted in green). NES= normalized enrichment score, FDR= false discovery rate
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Our analysis also identified altered expression of several
known neuroblastoma-associated genes that would be
predictive of unfavorable neuroblastoma outcome
(Supplementary Figure S3b, Supplementary Table S7a).
These include decreased levels of Ntrk1, Ntrk3 that are
associated with poorly differentiated tumors and poor
Fig. 4 Functional category enrichment analysis of differentially expressed genes in EµMyc/Casp2−/−tumors. a Gene Ontology annotation
analysis summary of the top 10 enriched biological processes associated with unique upregulated genes in EµMyc/Casp2−/− tumors (n= 159).
Complete lists are provided in Supplementary Table S5b. b Pathway enrichment analysis (KEGG and REACTOME), of the differentially expressed
upregulated genes in EµMyc/Casp2−/− tumors (n= 159). Complete lists are provided in Supplementary Table S6b. The number of genes associated
with each biological process and pathway is indicated. Dotted line indicates significance cut off (-log10 (P-value), Fisher's exact test). c Illustration of
gene set enrichment analysis (GSEA) score curves. Enrichment plots are shown for the identified upregulated and downregulated pathways from the
EµMyc/Casp2−/− tumor comparison group. Black bars represent the position of members of the category in the ranked list together with the running
enrichment score (plotted in green). NES= normalized enrichment score, FDR= false discovery rate
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prognosis in neuroblastoma40,41 (Fig. 5a, Supplementary
Table S7a). We also did not find significant changes in
other neuroblastoma marker genes (e.g., Bcl2, Cd44, Dcc,
Ddx1, Lmo1, Max, Mdr1/Abcb1, Mrp/ Abcc1, Nf1, Ngf,
Ntf3, Ntrk2, Nme1, Odc1, Rb1, Trp53)39 (Supplementary
Table S2a). These findings importantly show that these
genes do not necessarily have a role in delayed tumor
onset in Th-MYCN/Casp2−/− and/or their role in neu-
roblastoma onset may be counteracted by loss of Casp2.
Gene ontology analysis of the significantly altered
neuroblastoma genes indicated their involvement in
synaptic transmission, monoamine transport and cell
growth regulation (Fig. 5c, Supplementary Table S7b).
Interestingly, many of these genes are associated with
melanogenesis, dopaminergic synapse, Wnt, and Hippo
signaling (Fig. 5d, Supplementary Tables S7a and S7c).
Downregulation of melanogenesis is associated with
reduced expression of the transcription factor Mitf, along
with Wnt signaling pathway components (Fzd1, Lef1,
Camk2a). We noted a trend of altered expression of other
Wnt signaling components (Wnt5a, Dkk2, Bmp6; FDR >
0.1) and their regulators, including Gata2 and its target
homeobox transcription factors Six3 and Hesx1 (Supple-
mentary Tables S2a, S7a), which also have roles in neural
determination42,43. Increased expression of Wnt5a and
Fzd1 and decreased expression of Lef1 and Camk2a were
validated in different tumor samples by quantitative
PCR (Fig. 6a, b). Together, these data identify altered
expression levels of several Wnt-associated genes
and suggest a fine-tuning of Wnt signaling components in
Fig. 5 Differentially expressed genes in Th-MYCN/Casp2−/−tumors associated with survival in neuroblastoma patients. a Heat-map
illustrating the increase (red) and decrease (blue) in expression (log2-fold change) of various neuroblastoma-associated genes in Th-MYCN/Casp2−/−
tumors compared to Th-MYCN tumors. Gene lists and pathway associations are available in Supplementary Table S7a. b Event-free survival curves for
neuroblastoma patients from publicly available expression array data showing the expression correlation of the indicated genes with survival
outcome in neuroblastoma. P-values using the method of Kaplan–Meier (Bonferroni correction) are shown. c Gene Ontology annotation analysis of
the significantly enriched biological processes (Benjamini adjusted P-value < 0.05), associated with the genes listed in (a), that show altered gene
expression (FDR < 0.1) and are strongly associated with neuroblastoma outcome in (b) (n= 41). Complete gene ontology lists are provided in
Supplementary Table S7c. d Pathway enrichment analysis (KEGG) associated with neuroblastoma-associated genes above (n= 41). Complete
pathway enrichment lists are provided in Supplementary Table S7d. The genes associated with each biological process and pathways are indicated.
Dotted line indicates significance cut off [-log10(P-value), Benjamini corrected]
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Th-MYCN/Casp2−/− tumors that may determine neural
crest cell (NCC) specification to influence neuroblastoma
onset.
Differential expression of genes in caspase-2 deficient
tumors associated with enhanced EuMyc lymphoma
To identify candidate oncogenes and tumor suppressor
genes differentially expressed in the EμMyc/Casp2−/−
tumors that may contribute to enhanced lymphomagenesis,
we interrogated several published cancer gene lists44–46 and
databases (Sanger Cancer Gene Consensus; Bushman Lab
‘allOnco’ list; Oncogene Tumor Suppressor Gene
Resource). This analysis identified a 147-gene signature in
the EμMyc/Casp2−/− tumors that included increased
expression of a set of 72 oncogenes, decreased expression of
nine genes with known or predicted tumor suppressor
functions and 12 genes reported to have both oncogenic
and tumor suppressor functions (Figure S7a, Supplemen-
tary Table S8a). Many oncogenes have previously been
associated with EμMyc-mediated tumor progression and/or
B-cell lymphoma47–50. Several of these genes are clustered
on nearby chromosome regions, including Ch.4 (Megf6-
Prdm1, Arhgef16), Ch.6 (Cd4-Lag3, Cd8b-Cd8a), Ch.9
(Cd3d, Cd3g, Cd3e), Ch.10 (Dgka-Pme1), and Ch.11 (Sgsh,
Slc26a11, Card14) (Supplementary Table S8b) indicative of
possible common regulatory elements or amplification of
these regions in the EμMyc/Casp2−/− tumors. These
findings highlight changes in the expression of multiple
cancer-associated genes and/or gene regions that likely
contribute to enhanced EμMyc lymphomagenesis onset.
The majority of the genes that make up the Myc core
signature (MCS), associated with lymphoma malignancy
and progression51 were not further altered in EμMyc/
Casp2−/− compared to EμMyc tumors (Fig. 7, Supple-
mentary Table S8a). Interestingly, we found nine common
upregulated genes, which form part of the Bcor expression
signature in EμMyc mice52, (Bcl6, Camkk1, Cr2, Hivep3,
Kcnb1, Lef1, Slamf1, St3gal5, Ube2l6) (Supplementary
Table S8a). However, there was no evidence of an asso-
ciated increase in TGFβ signaling components in EμMyc/
Casp2−/− tumors, suggesting that Bcor-associated TGFβ
signaling may not contribute to enhanced lymphomagen-
esis in EμMyc/Casp2−/− mice.
Analysis of the 147-gene signature in EμMyc/Casp2−/−
tumors, identified axonogenesis, T-cell signaling, protein
kinase B signaling, and signal transduction as the top
enriched BPs and MFs (Fig. 7b, Supplementary
Table S8c). Consistent with this, T-cell receptor signaling,
primary immunodeficiency and hematopoietic cell lineage
were the top enriched KEGG pathways (Fig. 7c, Supple-
mentary Table S8d), with Rap1 signaling and cell adhesion
molecules also identified from our total DEG list (Fig. 4e).
This indicates the DEGs in EμMyc/Casp2−/− tumors are
largely established cancer-associated genes.
Interestingly, the pathways melanogenesis and Wnt
signaling were identified in the DEGs from both
Fig. 6 Validation of the differential expression of Wnt pathway associated genes in Casp2−/− tumors. Quantitative PCR analysis of the Wnt
pathway associated genes Wnt5a, Fzd1, Tcf7, and Lef (a) and CamkII family members Camk2a, Camk2b, Camk2g (b) in EµMyc/Casp2−/− and Th-MYCN/
Casp2−/− tumors as indicated. Values represent mean ± S.E.M, with P-values indicated (n= 8–11/group)
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[EμMyc/Casp2−/− v EμMyc] (Fig. 7c, Supplementary
Table S8d) and [Th-MYCN/Casp2−/− v Th-MYCN]
(Fig. 5d) tumor comparisons. Increased expression of
Tcf7, and its co-operating transcription factor Lef1, were
further confirmed by quantitative PCR analysis in dif-
ferent EμMyc/Casp2−/− tumor samples (Fig. 6a).
Comparison of DEGs in EμMyc/Casp2−/− compared to
Th-MYCN/Casp2−/− tumors
We compared the DEGs from EμMyc/Casp2−/− to
Th-MYCN/Casp2−/− tumors in aim to define unique
components and pathways associated with enhanced
EμMyc-mediated lymphomagenesis. A 4-way Venn
diagram identified 659 uniquely upregulated and 374
downregulated genes in the EμMyc/Casp2−/− compared
to Th-MYCN/Casp2−/− tumors (Fig. 8a). An additional
14 genes (Abcc2, Ccdc27, H19, Itgax, Krt17, Megf6, Mitf,
Mmp12, Rcn1, Rorc and Amy1, Col5a3, Kcnk1, Pitpnm2)
were differentially regulated compared to the EμMyc v
Th-MYCN DEGs (Supplementary Table S4c), with some
genes significantly associated with extracellular matrix
organization (Mmp12, Col5a3, Itgax) (GO:0030198,
Benjamini corrected P= 0.047), highlighting an impor-
tant difference in the EμMyc/Casp2−/− tumors.
Gene ontology analysis of the exclusively upregulated
genes (n= 659) identified the BPs immune response,
inflammatory response, angiogenesis, and cell migration
(Benjamini corrected P < 0.05) (Supplementary Fig-
ures S4a-b, Supplementary Tables S5c-d). Interestingly,
regulation of apoptosis, response to hypoxia, reactive
oxygen species, metabolic process and hematopoietic
progenitor cell differentiation are processes consistent
with loss of caspase-2 function6 (Supplementary Fig-
ure S4b, Supplementary Table S5d). Analysis of the
downregulated genes (n= 374) identified 13 unique BPs,
with neuron maturation being the most significantly
decreased, perhaps consistent with its primary role in Th-
MYCN/Casp2−/− tumors (Benjamini corrected P < 0.05).
Other notable downregulated pathways (e.g., response to
fatty acid, ubiquitination, negative regulation of epithelial
cell proliferation, and cell cycle arrest) highlight multiple
uniquely deregulated processes, previously been linked to
Casp2 loss, and suggest their role in contributing to
enhanced lymphomagenesis in EμMyc/Casp2−/−mice.
KEGG pathway analysis identified increased
Rap1 signaling and cytokine-cytokine receptor interaction
as the most significantly enriched and unique pathways
(P<0.001, Fisher's exact test) (Fig. 8b, Supplementary
Tables S6c-d). In addition to T-cell receptor signaling
identified from the above analysis (Fig. 4b), enrichment of
NFκB signaling and cytosolic-DNA sensing were
also confirmed by GSEA (Fig. 8c) (Supplementary
Table S6d). Interestingly, endocytosis was the top pathway
associated with downregulated genes (Benjamini
Fig. 7 Differentially expressed genes in EµMyc/Casp2−/− tumors
associated with cancer progression. a Heat-map illustrating the
increase (red) and decrease (blue) in expression (log2-fold change) of
various cancer-associated genes in EµMyc/Casp2−/− tumors. b Gene
Ontology annotation analysis of the top 20 significantly enriched
biological processes (Benjamini adjusted P < 0.05), associated with the
genes listed in (a), that show changes in gene expression (FDR < 0.1)
(n= 147). The number of genes associated with each biological
process is indicated. Complete gene ontology lists are provided in
Supplementary Table S8c. c Pathway enrichment analysis (KEGG
and REACTOME), of the cancer-associated genes differentially
expressed in EµMyc/Casp2−/− tumors (n= 147). The top 20
enriched pathways are shown. Complete enriched pathway lists are
provided in Supplementary Table S8d. The genes associated with
each pathway are indicated. Dotted line indicates significance cut
off (-log10(P-value), Benjamini corrected)
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Fig. 8 Comparison of differentially expressed genes and enriched pathways in EµMyc/Casp2−/− and Th-MYCN/Casp2−/− tumors. a Four-way
Venn diagram summary of unique and overlapping upregulated and downregulated genes in the indicated comparison groups. The list of unique and
overlapping genes in each group is provided in Supplementary Tables S4c and S4d. b KEGG Pathway enrichment analysis of upregulated (red) and
downregulated (blue) pathways in EµMyc/Casp2−/− tumors compared to Th-MYCN/Casp2−/− tumors. Number of genes associated with each pathway is
indicated. Complete enriched pathway lists are provided in Supplementary Table S6d. Dotted line indicates significance cut off (-log10(P-value) Fisher's
exact test). c GSEA of the upregulated and downregulated pathways from (b). Black bars represent the position of members of the category in the ranked
list together with the running enrichment score (plotted in green). NES= normalized enrichment score, FDR= false discovery rate
Dorstyn et al. Cell Death and Disease           (2019) 10:56 Page 11 of 16
Official journal of the Cell Death Differentiation Association
corrected P= 0.049), a process that has emerged as a key
hallmark of cancer, by affecting cell surface expression of
critical molecules and signaling processes53. Calcium
signaling, and Hippo signaling pathways were also
uniquely enriched (Fig. 8b, Supplementary Table S6d).
Consistent with this, reduced expression of Camk2a and
Camk2b was validated in different EμMyc/Casp2−/−
tumor samples (Fig. 6b). These findings highlight several
new pathways that are deregulated in EμMyc/Casp2−/−
tumors that can contribute to tumorigenesis.
Discussion
We used transcriptome profiling to characterize gene
expression changes and pathways affected by Casp2
deficiency, in tumors from Th-MYCN neuroblastoma30
and EμMyc lymphoma transgenic mouse models7. Our
study has identified specific caspase-2 expression sig-
natures in the different tumor types that likely contribute
to the distinct tumor outcomes7,30. The diversity in gene
expression highlights the (1) heterogeneity in tumor cell
populations and/or clonal co-operation between sub-
clones within the same tumor (2) tumor type-specificity
(3) aberrations in components of several different sig-
naling pathways, and/or (4) subtle differences that make it
difficult to detect single causative pathways.
While the changes in gene expression between the Th-
MYCN/Casp2−/− and EμMyc/Casp2−/− comparison
groups were distinct, it was interesting that Megf6 was the
only gene differentially expressed in the Casp2−/− tumors.
Megf6 is implicated in neural system disorders, such as
ataxia54 and recently, the epithelial-to-mesenchyme
transition (EMT) to promote metastasis in colorectal
cancer via TGFβ signaling55. Consistent with a tumor
progression function, we found higher expression of
Megf6 in EμMyc/Casp2−/− and lower expression in Th-
MYCN/Casp2−/− tumors. Lower levels of Megf6 expres-
sion also correlated with better survival outcome in
human neuroblastoma, suggesting it may contribute to
delayed neuroblastoma in the Th-MYCN/Casp2−/−
mouse30. The lack of clinical correlation with Megf6
expression in B-cell lymphoma may be indicative of a
tissue-specific function for Megf6 and/or that Casp2 loss
can cooperate with high Megf6 expression to augment
lymphomagenesis in the EμMyc/Casp2−/− model.
Nevertheless, these findings provide premise to further
investigate Megf6 role and potential co-operation with
caspase-2 function in tumorigenesis.
The delayed neuroblastoma onset in Th-MYCN/Casp2−/−
mice, previously highlighted the tissue/context specific role
for caspase-2 in tumor suppression30. Our study has now
identified cell differentiation as the most significantly altered
biological process in Th-MYCN/Casp2−/− tumors, asso-
ciated with downregulation of genes that regulate neuronal
differentiation and cell fate determination (Ascl2, Gldn, Mitf,
Notch3, Shb, Syt17) and many being transcription factors
(Ascl2, Batf3, Cbfa2t3, Elf4, Gata2, Mitf). A role for caspase-
2 in neuronal differentiation, remodeling and protection
against ischemic injury, has been previously impli-
cated34,56,57. Silencing Casp2 can increase expression of
neuronal differentiation markers57, and increased differ-
entiation in Casp2−/− neurons, would be consistent with
favorable neuroblastoma outcome40 and delayed tumor
onset in Th-MYCN/Casp2−/− mice30. Increased neuronal
differentiation is also associated with high ROS levels58, a
feature of Casp2−/− cells14,15, that can further contribute to
neuronal differentiation58. Identification of caspase-2 sub-
strate(s) and/or interacting partners in differentiating NCCs
will be key to defining its role in neurons and elucidate its
function in neuroblastoma.
Our analysis identified a 41-gene signature in
Th-MYCN/Casp2−/− tumors, associated with neuro-
blastoma outcome, and involved in altered melanogenesis,
Wnt and Hippo pathway signaling. Melanogenesis is
known to be inhibited by excessive ROS59 and may
therefore be affected by the increased oxidative stress and
ROS in Casp2−/− cells14,15. Melanogenesis is also asso-
ciated with aggressive neuroblastoma, characterized by
higher tyrosinase activity and associated increase in
DOPA synthesis60–62. The key regulator of tyrosinase is
Mitf, was significantly reduced in Th-MYCN/Casp2−/−
compared to Th-MYCN tumors, and may suggest a defect
in DOPA synthesis in Th-MYCN/Casp2−/− tumors,
consistent with the reduction in Dopaminergic synapse
signaling. In addition, Wnt signaling regulates melano-
genesis by stabilization and signaling through Mitf59.
While a role for Wnt signaling in neuroblast differentia-
tion has been described43,63, it has diverse functions in cell
proliferation, polarity and migration, so its role in neu-
roblastoma is likely complex63. Nevertheless, the finding
here, show that loss of Casp2 affects several components
regulating the Wnt signaling pathway in neuroblastoma,
that could impact neuronal differentiation and possibly
neuroblastoma onset in Th-MYCN/Casp2−/− mice.
Our previous studies demonstrated that loss of Casp2
accelerates EμMyc-driven lymphomagenesis7. This study
has now identified aberrant expression of 147 cancer-
associated genes including increased expression of 72
oncogenes and reduced expression of 9 TSG in the
EμMyc/Casp2−/− tumor samples. While many of these
genes may play co-operating roles with Casp2 loss to
enhance EμMyc-mediated lymphomagenesis, aberrant
expression of some genes are likely a consequence of
enhanced tumor growth caused by Casp2 loss. Interest-
ingly, the key pathways associated with EμMyc/Casp2−/−
tumors, was increased immune response, in particular T-
cell activation and signaling pathways. Higher expression
of CD4, CD25/IL2ra and Lag3 in EμMyc/Casp2−/−
tumors, are indicative of activated regulatory T-cells
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(Tregs) at the tumor site, which are associated with both
favorable and unfavorable prognosis in B-cell lympho-
mas64. They can facilitate tumor immune evasion by
directly suppressing B-lymphoma cells, and also function
to inactivate tumor specific CD4+/CD8+ T-cells, leading
to an immunosuppressive network associated with
increased T-cell tolerance and reduced T-cell mediated
killing64. This is a key factor in uncontrolled tumor
growth and poor clinical outcome in many solid tumors64.
Several clinical studies have also described the presence of
T-cell markers (including CD3, CD4, CD8) in diffuse large
B-cell lymphoma (DLBCL), but the prognostic sig-
nificance of this is not clear65. Our data are highly sug-
gestive that the active immune response plays a key role in
augmenting tumorigenesis in EμMyc/Casp2−/− mice. A
role for caspase-2 in regulating inflammasome signaling
and the innate immune response has been previously
reported6. However, it is also likely that the potential role
of caspase-2 in hematopoietic cell differentiation, (e.g.,
myeloid cell differentiation)66 may contribute to immu-
nosurveillance mechanisms that determine tumor
outcomes.
The comparison of gene expression profiles in EμMyc/
Casp2−/− tumors to Th-MYCN/Casp2−/− tumors iden-
tified a significant enrichment of genes associated with
Rap1 signaling. Rap1 regulates cell adhesion; a process
also enriched in the EμMyc/Casp2−/− tumors, and per-
haps indicates a link between these two processes. While
Rap1 can promote tumor cell migration, invasion, and
metastasis67, these features have not been observed in
EμMyc/Casp2−/− mice, indicating possible alternative
roles for Rap1 signaling in EμMyc/Casp2−/− tumors. This
may include Rap1 roles in regulating cytoskeletal
dynamics and/or cell proliferation, previously associated
with loss of caspase-2 function6,12. Alternatively,
Rap1 signaling plays diverse roles in hematopoietic cells,
including lymphocyte activation, migration/trafficking,
immunological synapse67, B-cell development, and self-
tolerance68. While the specific and diverse functions of
Rap1 are context dependent, a role for caspase-2 in reg-
ulating Rap1 signaling is highly relevant to lymphoma
onset and progression and will be important to further
define the contributing roles of Rap1 and caspase-2 in B-
cell lymphomagenesis.
In summary, this is the first description of tissue specific
and differential gene expression signatures associated with
caspase-2 deficiency that can influence tumorigenesis. In
particular, our findings indicating that loss of Casp2
impacts neuronal differentiation, is likely a key contributor
to delaying neuroblastoma onset and reduced adrenal
tumor development in Th-MYCN/Casp2−/− mice. In con-
trast, increased immune processes, including hematopoietic
cell lineage determination, are potential effectors in EμMyc/
Casp2−/− lymphomagenesis. In addition, we have identified
aberrant expression of several oncogenes and tumor sup-
pressor genes that potentially co-operate with Casp2 loss,
to determine tumor outcome. These findings reinforce the
distinct contribution of signaling pathways associated with
tumor onset and progression in both Th-MYCN/Casp2−/−
and in EμMyc/Casp2−/− mice.
Methods
Tumor samples
Lymphomas from EuMyc and EuMyc/Casp2−/− mice
were taken from cervical lymph nodes7. Tumor samples
from Th-MYCN and Th-MYCN/Casp2−/− mice were
selected from paraspinal thoracic tumors based on
absence or reduced blood vascularization30. Four indivi-
dual tumors per genotype were used for mRNA-seq
analysis.
RNA extraction
Total RNA was extracted from frozen tumor tissue
using Trizol® reagent (Life Technologies) according to the
manufacturer’s protocol. RNA was resuspended in die-
thylpyrocarbonate-(DEPC) treated water and quantified
using a NanoDrop1000™ spectrophotometer (Thermo
Scientific). RNA samples were quality tested using a 2100
Bioanalyser (Agilent Technologies) to confirm RNA
integrity number (RIN) > 7.
mRNA sequencing and bioinformatics analysis
RNA-seq and bioinformatics analysis was carried out at
the ACRF Cancer Genomics Facility (Centre for Cancer
Biology, UniSA). Briefly, polyA+ mRNA was enriched
using oligo-dT beads and samples were barcoded for
pooled sequencing on an Illumina HiSeq 2000 (Agilent
Technologies). Short, single-end reads were carried out
(1 × 50 bp flow cells) with four samples per lane. This
yielded ~20–30 million raw reads per sample.
Sequence quality was analyzed using FastQC and
the resulting data sets were aligned using the STAR align-
ment algorithm (https://www.ncbi.nlm.nih.gov/pubmed/
23104886) to the UCSC mm10/GRCm38 version of the
Mus musculus reference genome. Gene counts were
obtained from the second strand of the STAR output and
the resulting files were transferred to the R statistical
environment. The edgeR Bioconductor package69 was used
to fit a linear model and samples were log transformed for
normalization and ranking and then expressed as log2-fold
change of expression (Log2FC). Data are available in Gene
Expression Omnibus (GEO) under accession GSE124051.
Multidimensional scaling plots were generated to
explore the relationships in the data before and after
processing. (Supplementary Figure S1a and Supplemen-
tary Table S1c). All biological replicates were similar to
each other except for EμMyc/Casp2−/− sample #212,
which fell outside the EμMyc cluster. Normalization of
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data was able to correct for this, however a scatterplot
matrix analysis of the EμMyc samples indicated that
sample #212 was a strong outlier (Supplementary Fig-
ure S1a) and did not correlate well with other biological
replicates (Supplementary Figure S1b). For this reason,
EμMyc/Casp2−/− sample #212 was removed from further
differential expression analysis.
Differential expression analysis of individual genes
Differential expression analysis of individual genes was
carried out using edgeR. We divided samples into the two
tumor types EµMyc and MYCN groups, and also into two
genotype groups Casp2+/+ and Casp2−/−. Four-way com-
parisons in gene expression levels were made, including: (1)
Th-MYCN/Casp2−/− versus Th-MYCN; (2) EuMyc/
Casp2−/− versus EuMyc; (3) EuMyc versus Th-MYCN, and
(4) EuMyc/Casp2−/− versus Th-MYCN/Casp2−/−. Lastly
we carried out an additional analysis of the differentially
expressed factors caused by Casp2 loss in EµMyc compared
to Th-MYCN tumors; (EµMyc v EµMyc/Casp2−/−) versus
(Th-MYCN v Th-MYCN/Casp2−/−). Raw counts were
extracted for each of these samples and edgeR was used to
calculate the DEGs between the two phenotypic groups and
expressed as log2-fold change (Log2FC) of expression
between conditions being tested. Significant changes in
gene expression levels were determined using adjusted P-
values according to the Benjamini–Hochberg method to
control for the false discovery rate (FDR) (Supplementary
Tables S1c and S2a-f). For heat-maps, samples were clus-
tered based on gene expression levels and false discovery
rate (FDR < 0.05), and the most variable genes plotted
(Fig. 1c, d, Supplementary Figures S2d-f, Supplementary
Tables S3a-e).
Enrichment analysis of biological processes and pathways
Analysis of Gene Ontology and enriched biological
pathways was carried out on DEGs with log2FC > 1 and ≤
−1 (i.e., 2^(1); equivalent to an actual fold change of
2).(FDR < 0.05), using the Functional Annotation Tool in
the Database for Annotation, Visualization and Integrated
Discovery (DAVID) Bioinformatics Resources 6.8 (https://
david.ncifcrf.gov/home.jsp)70,71. Enriched pathways were
analyzed from the KEGG (Kyoto Encyclopedia of Genes
and Genomes) and REACTOME database in DAVID. The
threshold value of gene counts was set at 3, and the EASE
score was set at 0.1 and pathways with Fisher's exact P <
0.05, were considered to be enriched. Where indicated,
pathways were also determined using PANTHER72
(http://www.pantherdb.org/about.jsp) and EnRichR
(http://amp.pharm.mssm.edu/Enrichr/)73,74 databases.
Gene Set Enrichment Analysis (GSEA) of pathways and
genes was performed using Bioconductor fast pre-ranked
GSEA (fgsea) package in R.
Real-time quantitative PCR (qPCR)
Total RNA extracted from frozen tumor tissue, was
reverse transcribed using the High Capacity cDNA
Reverse Transcription Kit (Applied Biosystems) with
MultiScribe™ Reverse Transcriptase and oligo-dT
primers. Gene expression was normalized to the house-
keeping gene β-actin and then expressed as fold change
compared to EµMyc or Th-MYCN/Casp2+/+ tumor
samples, using the 2−ΔΔCt method. See Supplementary
Table S9 for primer sequences.
Statistical analyses
Statistical analysis was carried out using GraphPad
Prism software (v 6.0, San Diego, CA, USA). Data are
expressed as mean ± SEM and two-tailed unpaired t-test
with Welch’s correction was used for pair-wise compar-
isons, unless otherwise indicated. Heat-maps were gen-
erated using R software, from natural log2 transformed
data. Venn diagrams were generated using online software
jvenn (http://jvenn.toulouse.inra.fr/app/example.html)75.
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